The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GKOS | -25.51% | +56.38% | +9.34% | +240% |
| S&P | +14.18% | +88.25% | +13.47% | +226% |
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
The company's recent past featured robust growth, and it anticipates continued rises into the near future.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $133.54M | 38.1% |
| Gross Profit | $104.71M | 41.3% |
| Gross Margin | 78.41% | 1.8% |
| Market Cap | $4.68B | -34.7% |
| Market Cap / Employee | $4.70M | 0.0% |
| Employees | 995 | 9.7% |
| Net Income | -$16.23M | 24.2% |
| EBITDA | -$6.18M | 60.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $98.25M | -1.9% |
| Accounts Receivable | $98.68M | 74.9% |
| Inventory | 63.9 | 6.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $104.32M | -33.6% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -9.10% | 6.9% |
| Return On Invested Capital | -12.31% | -3.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.73M | -6.2% |
| Operating Free Cash Flow | -$10.09M | -5.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 12.36 | 7.24 | 7.67 | 6.10 | -43.17% |
| Price to Sales | 21.73 | 13.78 | 13.65 | 9.96 | -49.93% |
| Price to Tangible Book Value | 24.81 | 12.70 | 13.32 | 10.91 | -50.61% |
| Enterprise Value to EBITDA | -518.80 | -473.14 | -439.26 | -730.36 | 61.90% |
| Return on Equity | -23.8% | -20.4% | -13.0% | -12.2% | -53.31% |
| Total Debt | $105.87M | $105.48M | $105.02M | $104.32M | -33.61% |
No podcast episodes available.
GKOS earnings call for the period ending November 29, 2021.
GKOS earnings call for the period ending October 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
